Literature DB >> 23580333

Lysosomal impairment in Parkinson's disease.

Benjamin Dehay1, Marta Martinez-Vicente, Guy A Caldwell, Kim A Caldwell, Zhenyue Yue, Mark R Cookson, Christine Klein, Miquel Vila, Erwan Bezard.   

Abstract

Impairment of autophagy-lysosomal pathways (ALPs) is increasingly regarded as a major pathogenic event in neurodegenerative diseases, including Parkinson's disease (PD). ALP alterations are observed in sporadic PD brains and in toxic and genetic rodent models of PD-related neurodegeneration. In addition, PD-linked mutations and post-translational modifications of α-synuclein impair its own lysosomal-mediated degradation, thereby contributing to its accumulation and aggregation. Furthermore, other PD-related genes, such as leucine-rich repeat kinase-2 (LRRK2), parkin, and phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1), have been mechanistically linked to alterations in ALPs. Conversely, mutations in lysosomal-related genes, such as glucocerebrosidase (GBA) and lysosomal type 5 P-type ATPase (ATP13A2), have been linked to PD. New data offer mechanistic molecular evidence for such a connection, unraveling a causal link between lysosomal impairment, α-synuclein accumulation, and neurotoxicity. First, PD-related GBA deficiency/mutations initiate a positive feedback loop in which reduced lysosomal function leads to α-synuclein accumulation, which, in turn, further decreases lysosomal GBA activity by impairing the trafficking of GBA from the endoplasmic reticulum-Golgi to lysosomes, leading to neurodegeneration. Second, PD-related mutations/deficiency in the ATP13A2 gene lead to a general lysosomal impairment characterized by lysosomal membrane instability, impaired lysosomal acidification, decreased processing of lysosomal enzymes, reduced degradation of lysosomal substrates, and diminished clearance of autophagosomes, collectively contributing to α-synuclein accumulation and cell death. According to these new findings, primary lysosomal defects could potentially account for Lewy body formation and neurodegeneration in PD, laying the groundwork for the prospective development of new neuroprotective/disease-modifying therapeutic strategies aimed at restoring lysosomal levels and function.
Copyright © 2013 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23580333      PMCID: PMC5131721          DOI: 10.1002/mds.25462

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  81 in total

1.  Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.

Authors:  Marija Usenovic; Adam L Knight; Arpita Ray; Victoria Wong; Kevin R Brown; Guy A Caldwell; Kim A Caldwell; Igor Stagljar; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2012-05-29       Impact factor: 6.150

2.  Lithium protects against oxidative stress-mediated cell death in α-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease.

Authors:  Yong-Hwan Kim; Anand Rane; Stephanie Lussier; Julie K Andersen
Journal:  J Neurosci Res       Date:  2011-06-24       Impact factor: 4.164

3.  CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.

Authors:  S Pablo Sardi; Jennifer Clarke; Cathrine Kinnecom; Thomas J Tamsett; Lingyun Li; Lisa M Stanek; Marco A Passini; Gregory A Grabowski; Michael G Schlossmacher; Richard L Sidman; Seng H Cheng; Lamya S Shihabuddin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

4.  ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome.

Authors:  Anne Grünewald; Björn Arns; Philip Seibler; Aleksandar Rakovic; Alexander Münchau; Alfredo Ramirez; Carolyn M Sue; Christine Klein
Journal:  Neurobiol Aging       Date:  2012-01-31       Impact factor: 4.673

5.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.

Authors:  Alfredo Ramirez; André Heimbach; Jan Gründemann; Barbara Stiller; Dan Hampshire; L Pablo Cid; Ingrid Goebel; Ammar F Mubaidin; Abdul-Latif Wriekat; Jochen Roeper; Amir Al-Din; Axel M Hillmer; Meliha Karsak; Birgit Liss; C Geoffrey Woods; Maria I Behrens; Christian Kubisch
Journal:  Nat Genet       Date:  2006-09-10       Impact factor: 38.330

6.  Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.

Authors:  Ozlem Goker-Alpan; Barbara K Stubblefield; Benoit I Giasson; Ellen Sidransky
Journal:  Acta Neuropathol       Date:  2010-09-14       Impact factor: 17.088

7.  Regulation of presynaptic neurotransmission by macroautophagy.

Authors:  Daniela Hernandez; Ciara A Torres; Wanda Setlik; Carolina Cebrián; Eugene V Mosharov; Guomei Tang; Hsiao-Chun Cheng; Nikolai Kholodilov; Olga Yarygina; Robert E Burke; Michael Gershon; David Sulzer
Journal:  Neuron       Date:  2012-04-26       Impact factor: 17.173

8.  Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.

Authors:  Jason P Covy; Elisa A Waxman; Benoit I Giasson
Journal:  J Neurosci Res       Date:  2012-07-30       Impact factor: 4.164

9.  Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein.

Authors:  Wai Haung Yu; Beatriz Dorado; Helen Yvette Figueroa; Lili Wang; Emmanuel Planel; Mark R Cookson; Lorraine N Clark; Karen E Duff
Journal:  Am J Pathol       Date:  2009-07-23       Impact factor: 4.307

10.  Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.

Authors:  Valerie Cullen; Maria Lindfors; Juliana Ng; Anders Paetau; Erika Swinton; Piotr Kolodziej; Heather Boston; Paul Saftig; John Woulfe; Mel B Feany; Liisa Myllykangas; Michael G Schlossmacher; Jaana Tyynelä
Journal:  Mol Brain       Date:  2009-02-09       Impact factor: 4.041

View more
  122 in total

1.  Spastic paraplegia proteins spastizin and spatacsin mediate autophagic lysosome reformation.

Authors:  Jaerak Chang; Seongju Lee; Craig Blackstone
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

2.  BAX channel activity mediates lysosomal disruption linked to Parkinson disease.

Authors:  Jordi Bové; Marta Martínez-Vicente; Benjamin Dehay; Celine Perier; Ariadna Recasens; Agnes Bombrun; Bruno Antonsson; Miquel Vila
Journal:  Autophagy       Date:  2014-03-26       Impact factor: 16.016

3.  Arylsulphatase A activity in familial parkinsonism: a pathogenetic role?

Authors:  Elena Antelmi; Giovanni Rizzo; Margherita Fabbri; Sabina Capellari; Cesa Scaglione; Paolo Martinelli
Journal:  J Neurol       Date:  2014-07-03       Impact factor: 4.849

4.  Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99).

Authors:  Ying Jiang; Yutaka Sato; Eunju Im; Martin Berg; Matteo Bordi; Sandipkumar Darji; Asok Kumar; Panaiyur S Mohan; Urmi Bandyopadhyay; Antonio Diaz; Ana Maria Cuervo; Ralph A Nixon
Journal:  J Neurosci       Date:  2019-05-01       Impact factor: 6.167

Review 5.  Molecular Mechanisms of Lysosome and Nucleus Communication.

Authors:  Qian Zhao; Shihong Max Gao; Meng C Wang
Journal:  Trends Biochem Sci       Date:  2020-07-02       Impact factor: 13.807

Review 6.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

7.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

8.  DNAJC13 mutations in Parkinson disease.

Authors:  Carles Vilariño-Güell; Alex Rajput; Austen J Milnerwood; Brinda Shah; Chelsea Szu-Tu; Joanne Trinh; Irene Yu; Mary Encarnacion; Lise N Munsie; Lucia Tapia; Emil K Gustavsson; Patrick Chou; Igor Tatarnikov; Daniel M Evans; Frederick T Pishotta; Mattia Volta; Dayne Beccano-Kelly; Christina Thompson; Michelle K Lin; Holly E Sherman; Heather J Han; Bruce L Guenther; Wyeth W Wasserman; Virginie Bernard; Colin J Ross; Silke Appel-Cresswell; A Jon Stoessl; Christopher A Robinson; Dennis W Dickson; Owen A Ross; Zbigniew K Wszolek; Jan O Aasly; Ruey-Meei Wu; Faycal Hentati; Rachel A Gibson; Peter S McPherson; Martine Girard; Michele Rajput; Ali H Rajput; Matthew J Farrer
Journal:  Hum Mol Genet       Date:  2013-11-11       Impact factor: 6.150

Review 9.  Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease.

Authors:  Daniel J Colacurcio; Ralph A Nixon
Journal:  Ageing Res Rev       Date:  2016-05-16       Impact factor: 10.895

Review 10.  Defective autophagy in Parkinson's disease: lessons from genetics.

Authors:  H Zhang; C Duan; H Yang
Journal:  Mol Neurobiol       Date:  2014-07-04       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.